DBV Technologies shares fall below €2 and erase rebound following FDA filing
The rebound welcomed yesterday following the regulatory filing with the FDA is completely erased today. DBV Technologies ranks among the steepest declines of the SBF 120 at midday, in a Paris index itself down more than 1%.
A decline of 6.7% that breaks through the €2 threshold and deepens the monthly performance
The stock loses 6.7% during the session at €1.94, after closing at €2.07 the previous day. The biotech company specialized in immunotherapy against food allergies has breached its €2 support level downward during the session and remains below at €1.94. This breach extends a marked negative momentum: the stock is down nearly 18.5% over one month and more than 31% over three months, erasing most of the rebound generated by the filing of the biological license application with the FDA on September 30.
The stock remains firmly below its three moving averages: the 20-day MA is at €2.17, a gap of 10.8% above the current price, while the 50-day MA at €2.32 is even further removed. The RSI at 42 reflects a neutral configuration with no immediate reversal signal.
Short selling positions on the rise, at 4.4% of declared capital
Beyond today's price movement, structural selling pressure is confirmed in the recorded declarations: four funds cumulatively hold 4.40% of DBV Technologies capital in net short positions, compared to 3.39% thirty days ago, representing an increase of 1.01 percentage points over the period. At this level, the bearish bet represents a genuine warning signal: it reflects persistent institutional distrust regarding the company, although the motivation of the participants cannot be determined with certainty (exposure hedging, dilution anticipation, directional bets). As a reminder, during the publication of first-half 2026 results on July 16, the company indicated it had a financing horizon until the third quarter of 2027, with no commercial revenues at this stage. The next identifiable regulatory milestone remains the FDA's response to the priority review request for the peanut patch, submitted on September 30.
